CollPlant Biotechnologies has the GF Score of 22, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes CollPlant Biotechnologies
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
CollPlant Biotechnologies GF Score Related Terms
FRA:CPT vs CPMV, TCRT, DRMA: GF Score Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's GF Score distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's GF Score falls into.
CollPlant Biotechnologies (FRA:CPT) has a GF Score of 22 as of Jul. 06, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on CollPlant Biotechnologies and its competitors. This is 45% below median its historical median of 40.00. Over the past decade, CollPlant Biotechnologies' GF Score has ranged from 16.00 to 52.00.
Is CollPlant Biotechnologies' GF Score too high?
CollPlant Biotechnologies' current GF Score of 22 is 45% below median its 10-year median of 40.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 52.00. Overall, CollPlant Biotechnologies has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' GF Score compare to CPMV and TCRT?
CollPlant Biotechnologies' GF Score of 22 can be compared against companies in the Biotechnology industry. Historically, CollPlant Biotechnologies' own GF Score has ranged from 16.00 to 52.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current GF Score is 22, which is 45% below median its own 10-year median of 40.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.23, compared to a current price of €0.27 — trading 15.7% above its estimated fair value. The current GF Score is 22, which is 45% below median its 10-year median of 40.00. CollPlant Biotechnologies' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current GF Score is 22 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of €0.27 is trading 15.7% above its estimated GF Value™ of €0.23.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for FRA:CPT:
GF Score: 22 (45% below median its 10-year median of 40.00)
GF Value™: €0.23 vs. price of €0.27 (15.7% above fair value)
No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
22GF Score
Get the complete analysis for FRA:CPT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CPT has been successfully added to your 